Search Results (675)

With global cancer cases projected to reach 35 million by 2050 and drug resistance to existing chemotherapeutic drugs remaining a significant threat in cancer therapy, accounting for up to 90% of chemotherapy failures, the search for novel anticancer compounds continues to be increasingly important. This systematic review (2021–2025) examined the role of thiazoles and 4-thiazolidinones/thiazolidinediones as popular scaffolds in existing anticancer drug design. While researchers continue to focus on well-established molecular targets, such as EGFR, VEGFR-2, and tubulin, there is a notable difference regarding other preferred choices for thiazoles and 4-thiazolidinones/thiazolidinediones. Among analyzed mechanisms of anticancer activity notably favored for thiazoles was the inhibition of serine/threonine protein kinases (CDK-2, BRAF^V600E), while for 4-thiazolidinones/thiazolidinediones more studied were ROS generation and PPARγ activation. Furthermore, less-researched mechanisms of anticancer activity with no FDA-approved drugs such as PTP1B, SIRT2, PKM2, eIF4E, CA XI and XII inhibition for thiazole derivatives and pan-PIM kinase and BAG3 protein inhibition for 4-thiazolidinones/thiazolidinediones were evaluated as well. Notable was the popularity of the multi-targeting approach for modern drug design, with ~30% reporting two or more targets for their compounds. Despite these advancements, the review identified critical gaps in ADMET evaluations, safety analyzing against normal human cells and the lack of mechanistic studies connecting the targeted protein and the compounds anticancer effects. Full article

Background: Platelet concentrates (PCs) are vital for treating hematologic disorders and thrombocytopenia, yet their short shelf life (3–5 days) is limited by platelet storage lesion (PSL)—a process involving biochemical and structural deterioration that reduces post-transfusion efficacy. This study aimed to characterize alterations in platelet surface receptors and RNA content during storage to better understand PSL mechanisms. Methods: Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were prepared from healthy donors and stored PCs. Flow cytometry was used to assess the expression of GPIbα, GPVI, Integrin αIIbβ3, and CD9. Thiazole orange (TO) staining evaluated RNA content to distinguish young from aged platelets, while soluble GPVI (sGPVI) levels were quantified by ELISA. Data were analyzed using one-way ANOVA and Student’s t-test (p < 0.05). Results: Baseline receptor profiles were established from fresh donor platelets. Stored PCs showed a progressive decline in GPIbα and GPVI expression from day 6, with significant reductions by day 11 (p < 0.05). αIIbβ3 expression decreased early (day 6) and stabilized thereafter, whereas CD9 remained unchanged. TO staining indicated a gradual loss of RNA-rich platelets, signifying aging. ELISA revealed increased sGPVI levels from day 6 to day 14, inversely correlating with surface GPVI loss. Conclusions: Prolonged storage leads to receptor degradation and platelet senescence, notably affecting GPIbα, GPVI, and αIIbβ3. Elevated sGPVI levels and reduced RNA content reflect progressive PSL. Flow cytometry and ELISA offer reliable monitoring tools, and sGPVI may serve as a biomarker for platelet quality during storage. Full article

The non-thermal plasma (NTP) process is a promising advanced oxidation process (AOP) for removing non-biodegradable organics from wastewater, owing to the efficient formation of reactive chemicals. Despite its effective oxidizing capability, the decomposition mechanism of organic pollutants is not well understood. This study evaluates NTP for two representative sulfonamides (SMZ and STZ) and reports on (i) time-resolved removal to the method detection limit, (ii) transformation mapping using LC-ESI/MS/MS, which confirmed previously proposed hydroxylation and bond-cleavage pathways and further identified additional hydroxylated intermediates formed on the thiazole and benzene rings under NTP conditions, and (iii) energy evaluation through energy per order (EEO) within a single, reproducible operating window. The EEO values for SMZ and STZ degradation via NTP were calculated at 22.4 and 7.5 kWh/m³/order, respectively. These values are up to 37- and 118-fold lower than those reported for comparable AOPs, quantitatively confirming that the proposed NTP process achieves superior energy efficiency for sulfonamide degradation. Degradation is primarily attributed to reactive oxygen species (ROS) generated by plasma, which initiate the breakdown of the antibiotic structure. Overall, this study demonstrates that NTP is a highly effective AOP for driving the rapid primary degradation and intermediate structural transformation of recalcitrant sulfonamide antibiotics. Full article

2-methylcamalexin, a novel derivative of the phytoalexin Camalexin, was synthesized for the first time, using a convenient two-step approach. The approach realizes coupling of two aromatic heterocyclic moieties (2-methylindole and thiazole) by sequential α-amidoalkylation/oxidative re-aromatization. The target product was obtained in a cost-effective manner, with 88% yield over two steps. The structure of the synthesized product was unequivocally determined on the basis of NMR, HRMS and FTIR spectral measurments. Full article

The development of novel antiepileptic agents requires early identification of pharmacokinetic limitations to mitigate risks at later stages. This study aimed to perform in silico profiling of a library containing 448 novel 2H,5H-chromeno[4’,3’:4,5]thiopyrano[2,3-d]thiazol-2-one derivatives to select lead compounds with an optimal balance of safety and efficacy. The study was conducted using the ADMET-AI platform, based on a graph neural network, to predict physicochemical, pharmacokinetic, and toxicological properties. The methodology involved calculating drug-likeness descriptors for primary screening and a comparative statistical analysis of the top 20 selected structures against 16 approved antiepileptic drugs and four reference compounds. Based on drug-likeness descriptors and predicted ADMET (absorption, distribution, metabolism, excretion, toxicity) related parameters, 20 structures were prioritized for further analysis. Their predicted profiles suggested high intestinal absorption and blood–brain barrier (BBB) permeability, which may be relevant for central nervous system (CNS) directed agents. In comparison with the reference thiazolidinones, the prioritized compounds showed comparatively more favorable predicted mutagenicity and carcinogenicity profiles. Elevated predicted risks of hepatotoxicity and cardiotoxicity were observed for several structures, indicating the need for further structural optimization. The results suggest that the thiopyranothiazolidinone scaffold merits further anticonvulsant-oriented investigation at the stage of early compound prioritization. Experimental validation will be required to confirm the actual pharmacokinetic, toxicological, and anticonvulsant properties of the prioritized compounds. Full article

The use of one-step products and their applications in sensory applications has gained much importance. Herein, Schiff’s base fluorescent turn-on sensor, namely FBTS, was synthesised via a condensation reaction between 6-fluorobenzo[d]thiazol-2-amine and 2-hydroxybenzaldehyde. The probe FBTS exhibits an intense “turn-on” blue fluorescence upon binding to Al³⁺ ions in a dimethyl sulfoxide–water (DMSO–H₂O (8:2, v/v)) medium. From photoluminescence (PL) titrations, the detection limit (LOD) for Al³⁺ is estimated to be 0.14 microM, and the Benesi–Hildebrand plot-based association constant (K_a) of 5.4 × 10⁴ M⁻¹ confirm a strong association between FBTS and Al³⁺. Negligible interference is observed in the presence of other metal ions. From the pH effect studies, the optimal pH range for Al³⁺ detection is 7–9. The recyclable reversibility of FBTS + Al³⁺ complex has been demonstrated via the sodium salt of ethylenediaminetetraacetic acid (Na₂-EDTA) chelation. A Job’s plot and interrogations, such as high-resolution mass spectrometry (HR-MS), ¹H-nuclear magnetic resonance (NMR) titration, and density functional theory (DFT), verified the 1:1 stoichiometry of binding between FBTS and Al³⁺. Based on multiple analyses, the binding mode and mechanism have been detailed. In addition, the practical application of FBTS for detecting Al³⁺ is demonstrated using the strip paper method, fish analysis, spiked real sample analysis, and cellular imaging. Full article

Psoriasis, a chronic inflammatory skin disease, is driven by immune dysregulation and keratinocyte hyperproliferation, with current biologics facing limitations. Emerging evidence points to mitochondrial dysfunction and a pathological shift to aerobic glycolysis as core disease drivers. Here, we report that MitoFu-O, a novel mitochondria-targeting TPP-thiazole derivative, effectively ameliorates psoriasiform inflammation in imiquimod-induced mice and cytokine-stimulated keratinocytes. Mechanistically, MitoFu-O acts by inhibiting pathological glycolysis, downregulating key glycolytic enzymes (HK1, GAPDH, LDHA), and subsequently suppressing the activation of pivotal pro-inflammatory signaling pathways (MAPK, NF-κB, and STAT3). Our findings establish targeted mitochondrial modulation as a potent therapeutic strategy, positioning MitoFu-O as a promising lead compound that acts upstream of cytokine signaling by normalizing the metabolic reprogramming fundamental to psoriatic pathogenesis. Full article

Multitarget-directed ligands offer a promising strategy for overcoming tumor complexity through simultaneous modulation of complementary oncogenic pathways. In this work, a novel (E)-6-(3-(4-methyl-2-thioxo-2,3-dihydrothiazol-5-yl)-3-oxoprop-1-en-1-yl)-2H-chromen-2-one (compound 6) was synthesized and evaluated as a dual inhibitor of tubulin polymerization and tumor-associated carbonic anhydrases (CAs) IX and XII. Compound 6 displayed potent antiproliferative activity, particularly against MDA-MB-231 triple-negative breast cancer cells (IC₅₀ = 0.37 µM), with excellent selectivity toward non-tumorigenic cells. Mechanistic studies demonstrated strong tubulin polymerization inhibition (IC₅₀ = 3.40 ± 0.09 µM) and submicromolar inhibition of CA IX (IC₅₀ = 0.102 ± 0.005 µM) and CA XII (IC₅₀ = 0.213 ± 0.004 µM), accompanied by downregulation of CA-IX and CA-XII protein expression. Cellular investigations revealed pronounced G₂/M phase arrest and apoptosis induction via mitochondrial signaling and caspase activation. Anti-angiogenic activity was supported by inhibition of endothelial migration and concentration-dependent suppression of VEGFR-2 (Tyr1175) phosphorylation in HUVEC cells. Human liver microsomal assays indicated measurable metabolic stability, while molecular docking and in silico ADMET predictions supported target engagement and drug-like properties. Collectively, these findings identify compound 6 as a promising multitarget anticancer lead integrating antimitotic, metabolic, and anti-angiogenic mechanisms. Full article

Background: Schistosomiasis affects more than 250 million people, and praziquantel remains the only drug available for treatment; however, its activity is restricted to adult worms. Previously, our group evaluated six thiazole derivatives (PBT1–PBT6) in vitro against adult Schistosoma mansoni, identifying PBT2, PBT5, and PBT6 as the most active compounds. The present study aimed to evaluate the in vitro activity of PBT2, PBT5, and PBT6 against schistosomula and juvenile worms, as well as their in vivo efficacy against adult S. mansoni. Methods: Mechanically transformed schistosomula and juvenile worms recovered from mice (21 days post-infection) were incubated with the compounds (12.5–200 μM). Cytotoxicity was assessed using murine splenocytes and peritoneal macrophages exposed to the same concentration range. For in vivo evaluation, infected mice were orally treated with compounds (50, 100, or 200 mg/kg) for five consecutive days. Results: All compounds induced 100% mortality in schistosomula and juvenile worms within 3 h of exposure at 100 and 200 μM. Parasite cell viability was markedly reduced (>90%) at concentrations between 50 and 200 μM. The LC₅₀ values ranged from 15.3 to 30.9 μM for schistosomula and from 27.8 to 34.9 μM for juvenile worms, with low cytotoxicity observed in mammalian cells (CC₅₀ ≥ 193.9 μM). In vivo treatment resulted in significant reductions in fecal egg counts (~80% at 200 mg/kg), total worm burden (~60%), and egg loads in liver and intestinal tissues, in addition to an increased proportion of dead eggs in the intestine. Conclusions: The evaluated thiazole derivatives demonstrated potent in vitro activity against immature stages of S. mansoni and significant in vivo efficacy against adult parasites, accompanied by favorable changes in key parasitological parameters. These findings reinforce the potential of thiazole-based compounds as promising multistage schistosomicidal candidates. Full article

Background/Objectives: Targeting ABL tyrosine kinase (TK) remains a cornerstone of chronic myeloid leukemia (CML) therapy. Methods: In this study, a series of novel 4-((2-(4-(aryl)thiazol-2-yl)hydrazineylidene)methyl)-N,N-diphenylaniline derivatives (1–12) were synthesized through the reaction of 2-(4-(diphenylamino)benzylidene)hydrazine-1-carbothioamide (intermediate A) with substituted 2-bromo-1-arylethanones. Cytotoxic activity was evaluated in K562 CML cells using the MTT assay. The most active compound was further assessed in HL-60 acute myeloid leukemia (AML) cells and healthy peripheral blood mononuclear cells (PBMCs). Apoptosis induction was analyzed by Annexin V/ethidium homodimer staining, while ABL TK inhibition was determined using the ADP-Glo kinase assay. Molecular docking studies were performed to investigate binding interactions within the ATP-binding site of ABL TK, and pharmacokinetic properties were also predicted. Results: Intermediate A demonstrated superior antiproliferative activity compared to derivatives 1–12 and exhibited cytotoxicity comparable to imatinib in K562 cells (IC₅₀ = 6.15 ± 1.26 µM vs. 5.14 ± 1.44 µM, respectively). In HL-60 cells, intermediate A showed an IC₅₀ of 12.04 ± 1.70 µM, similar to imatinib. Notably, intermediate A displayed enhanced selectivity toward K562 cells over PBMCs (SI = 12.9) relative to imatinib (SI = 6.2). The compound significantly induced apoptosis in K562 cells and inhibited ABL TK activity. Docking studies revealed a distinct binding orientation within the ATP-binding pocket of ABL TK. The compound showed acceptable predicted physicochemical and ADME characteristics based on in silico analysis. Conclusions: Intermediate A emerges as a significant anti-CML candidate exhibiting potent cytotoxic, apoptotic, and moderate ABL TK inhibitory activity, together with a favorable selectivity profile. Full article

Herein, a novel series of 4-piperidinylphenyl-linked thiazoles was synthesized as VEGFR2 inhibitors with potential cytotoxic activity against renal cancer. Most of the target compounds inhibited VEGFR2 enzyme at sub-micromolar IC₅₀ values. Compounds 7c (IC₅₀ = 0.073 ± 0.002 µM), 9b (IC₅₀ = 0.049 ± 0.002 µM), and 9c (IC₅₀ = 0.093 ± 0.003 µM) were the most potent, showing VEGFR2 inhibition superior to that of sunitinib (IC₅₀ = 0.118 ± 0.003 µM). Furthermore, compounds 7c, 9b, and 9c effectively inhibited the growth of A498 renal cancer cells, with compound 7c being the most potent showing a one-digit IC₅₀ value of 7.866 ± 0.27 µM. In addition, compound 7c revealed a potentially improved safety profile against non-cancerous normal cells, relative to sunitinib. The treatment of A498 renal cancer cells with compound 7c led to an apparent cell cycle arrest and a significant induction of apoptosis. A docking study was also conducted and revealed a proper orientation of compound 7c into the active site of VEGFR2. Full article

1,3-Thiazole derivatives are of interest in pharmacy, medicine, and agriculture as potential biologically active substances. We have proposed for the first time a convenient and effective method for the synthesis of amidoalkylated derivatives of 2-amino-1,3-thiazole. This approach is based on the reaction of amidoalkylated thioureas with α-halocarbonyl compounds. The reaction was carried out under stirring at 20 °C in ethanol with the addition of an equimolar amount of triethylamine to bind the released hydrogen halide. The yield of the obtained 1,3-thiazole derivatives was 68–75%. An attempt to carry out a counter-synthesis by amidoalkylation of the corresponding 2-amino-1,3-thiazole derivative was unsuccessful due to strong resinification of the reaction mass. The structure of the compounds obtained was confirmed by ¹H and ¹³C NMR spectroscopy. The structure was finally confirmed by X-ray structural analysis performed for N-(2,2,2-trichloro-1-((4-phenylthiazol-2-yl)amino)ethyl)acetamide. Full article

The search for new growth-regulating compounds remains a relevant research direction in view of the issue of food security. Previously, a number of thiazolyl acetic acid derivatives have been synthesized, which are promising biologically active compounds according to their physicochemical characteristics. The aim of this work was to study the growth-regulating properties of both previously and newly synthesized thiazolyl acetic acid derivatives using a growth phytotest with Lepidium sativum and Sinapis alba. This study was carried out under laboratory conditions of phytotesting growth indicators of test plants of the class Dicotyledones—L. sativum and S. alba under the influence of 10 μg/mL, 100 μg/mL, and 1000 μg/mL aqueous solutions of the compounds with a comparative analysis of the action of the active components of Rhizopon^TM and herbicide benazolin. It was found that, exhibiting high herbicidal properties at a concentration of 1000 μg/mL (primarily the compound with a benzothiazole fragment), the studied thiazolyl acetic acid derivatives with decreasing concentration (100 μg/mL and 10 μg/mL) reduce phytotoxicity to its complete elimination against L. sativum and S. alba for the compound 2-[2-(N-tert-butoxycarbonyl)-aminoethyl-1,3thiazol-4-yl]acetic acid (compound 3), as well as against L. sativum for the compound 5-phenylthiazol-2-yl acetic acid (compound 5). A weak stimulating effect on the length of the above-ground part of S. alba seedlings was recorded for 2-[2-(3,3,3-trifluoropropyl)-1,3thiazol-4-yl]acetic acid (compound 1) and 2-[2-(N-tert-butoxycarbonyl)-aminoethyl-1,3thiazol-4-yl]acetic acid (compound 3) at their concentration of 10 μg/mL; however, an improvement in the vitality index under the action of these compounds was not observed. The results obtained in this study indicate the biological activity of both previously and newly synthesized thiazolyl acetic acid derivatives, namely their growth-regulatory properties, expanding knowledge about promising herbicidal compounds with a possible hormetic effect, which requires further research. Full article

A novel series of benzothiazole scaffolds were presented to test their in vitro α-amylase and α-glucosidase activities for combating diabetes mellitus, which is one of the most rapidly growing diseases. The tested compounds were elucidated structurally by various spectroscopic techniques like ¹H NMR, ¹³C NMR and HRMS. All compounds exhibited a varied range of inhibitory activities against targeted α-amylase and α-glucosidase enzymes, with IC₅₀ values of 1.58 ± 1.20 to 7.54 ± 3.60 µM (α-amylase) and 2.10 ± 1.10 to 8.90 ± 4.10 (α-glucosidase), respectively. The obtained results were compared with the standard acarbose drug, with IC₅₀ values of 0.91 ± 0.20 µM (α-amylase) and 1.80 ± 1.10 µM (α-glucosidase). Specifically, methyl 2-amino-4-((6-methoxypyridin-3-yl)methoxy)benzo[d]thiazole-6-carboxylate (5c) and methyl 4-((6-methoxypyridin-3-yl)methoxy)-2-(thiazole-2-carboxamido)benzo[d]thiazole-6-carboxylate (6b) emerged as potent inhibitors of α-amylase and α-glucosidase enzymes. These potent compounds were further screened for in silico molecular docking studies to investigate possible binding interactions with active sites of targeted enzymes, and results obtained demonstrated that potent compounds exhibited stronger binding affinities toward anti-diabetic enzymes compared to the positive control acarbose. Full article

Despite notable progress in drug discovery, cancer treatment remains hindered by limited therapeutic efficacy, poor target specificity, adverse effects, and the development of drug resistance. Molecular hybridization, which integrates two or more bioactive entities into a single molecule, has shown considerable potential to overcome these limitations. Since both azoles and flavonoids have demonstrated anticancer potential, extensive studies have been undertaken to combine the two entities and enhance the bioactivity of the resulting hybrids. In this context, numerous azole–flavonoid hybrids have been synthesized and investigated for their anticancer potential. This review provides an overview of the azole–flavonoid hybrids that are promising candidates for novel anticancer drug development, highlighting their superior antitumor potency compared to reference drugs, multitarget activity, tumor-selective cytotoxicity, efficacy against drug-resistant tumor cells, and structure–activity relationships. The review covers 250 hybrids, primarily triazole–chalcone hybrids but also triazole–flavone, flavanone, flavonol, and isoflavone hybrids, as well as other azole–flavonoid hybrids (imidazole–, pyrazole–, isoxazole–, and thiazole–flavonoid hybrids). Full article